Prostaglandin E1
Recently Published Documents





Priya Ghosh ◽  
Aditi Chandra ◽  
Sumit Mukhopadhyay ◽  
Argha Chatterjee ◽  
Dayananda Lingegowda ◽  

2021 ◽  
Vol 17 (2) ◽  
pp. 108-114
Bongsoo Baik ◽  
Sulki Park ◽  
Soyoung Ji ◽  
Wansuk Yang ◽  
Junekey Lee

Background: When an avulsion wound is combined with a crushing injury or when a local flap is moved with significant tension, poor local blood supply may result in partial or complete necrosis of the involved tissue. This paper explores procedures to prevent tissue necrosis for the ischemic wounds.Methods: From March 2017 to December 2018, 29 hospitalized patients (group A) were treated with simple dressing change and administration of antibiotics. From January 2019 to October 2020, 29 hospitalized patients (group B) were injected for the first 3 days intravenously once a day with 50 μg of stabilized prostaglandin E1. Prostaglandin E1 injections were combined with supplemental oxygen (4 L/min through nasal cannula for 24 hours per day for the first 3 days). Wound dressing and antibiotics administration were also combined.Results: Ten patients in group A developed partial wound necrosis, out of which four patients received local flap surgery after excision of the necrotic tissue. The average recovery time was 9.7 days. In group B, four patients developed partial wound necrosis, out of which one was treated with local flap surgery. The average recovery for the four patients in group B took 6.2 days.Conclusion: Prostaglandin E1 and supplemental oxygen reduced the incidence of partial wound necrosis of ischemic wounds and local flap surgery after excision of the necrotic tissue, and also shortened the average recovery time.

Tomasz J. Nabialek ◽  
Naga K. Puppala ◽  
Andrew Riordan ◽  
Ram Ramaraj ◽  
Phuoc Duong ◽  

A six-week-old infant presented in extremis and was diagnosed with dextro-transposition of the great arteries, intact ventricular septum, features of left ventricular deconditioning, and abnormal coronary arteries. Treatment with prostaglandin E1 and balloon atrial septostomy was insufficient, necessitating extracorporeal membrane oxygenation (ECMO). Severe acute respiratory syndrome coronavirus-2 was detected. The arterial switch operation was delayed by eight days because of COVID-19. Although stable on ECMO, the infant was treated with remdesivir. Extracorporeal membrane oxygenation was not required postoperatively with chest closure on day 2 and extubation on day 5.

Paresh N. Sheth

Background: Misoprostol is prostaglandin E1 analogue that has been used for medical abortion. MTP has been legalized in India since 1971. Medical abortion refers for early pregnancy termination performed without any primary surgical interventions, usually before 9 weeks (63 days) gestational age. This prospective study was conducted to compare the efficacy of vaginal misoprostol for abortion in women at a gestational age of <6 weeks (42 days) and in woman up to 9 weeks (63 days) gestational age.Methods: This is a prospective study of total 130 women seeking medical termination of pregnancy up to 9 weeks (63 days) gestational age at obstetrics and gynecology department, at a tertiary care hospital Gujarat, India, from May 2018 to May 2019.Results: In result study the overall complete abortion rate was 91.54% In Group A (<6 weeks) complete abortion occurred in 93.3% women. Whereas in Group B (6 to 9 weeks) complete abortion occurred in 90% of women. The two groups did not differ significantly with respect to side effects. Overall, 91.3% women were satisfied with this method and will choose it again if required.Conclusions: This study shows that vaginal misoprostol alone regimen is highly effective and well tolerated method in Indian women requiring MTP up to 63 days gestational age. However better efficacy maybe achieved at gestational age < 6 weeks (42 days). 

Dheeraj Kapoor ◽  
Manju Sharma ◽  
Manpreet Singh ◽  
Shraddha Sinha ◽  
Binish Kathuria

Misoprostol is a synthetic prostaglandin E1 analogue and has been reccommended as a safe, effective, easy to administer, cost efficient next in line drug after oxytocin, for the treatment and prevention of postpartum haemorrhage (PPH). Notwithstanding, it causes certain undesirable side effects compared to oxytocin such as nausea, vomiting, shivering, diarrhoea and transient fever. Transient pyrexia is commonly related with misoprostol administration, due to shift of hypothalamic set point. However, hyperpyrexia clubbed with seizures is a rare yet self-limiting side effect and requires prompt management strategies. There have been case reports describing fever following misoprostol administration but only few describing hyperpyrexia and even fewer describing with seizures. We report a case of hyperpyrexia associated with delayed presentation of generalised sezuires after administration of rectal misoprotol and its successful management in critical care settings.

2021 ◽  
Vol 17 ◽  
Amar Taksande ◽  
Patel Zeeshan Jameel

: Critical congenital heart defects (CCHDs) are serious malformations which remain to be an important cause of neonatal mortality and morbidity. The clinical presentations of CCHD are shock, cyanosis or respiratory distress which may be similar to that of other neonatal conditions. Failure to diagnose these conditions early on after birth may result acute cardiovascular collapse and death. Screening with routine pulse oximetry is efficient in distinguishing newborns with CCHD and other hypoxemic illnesses, which may be otherwise be potentially life-threatening. If the cardiovascular system cannot be observed by echocardiography, then treatment with continuous prostaglandin-E1 (PGE1) infusion should be started in any newborn whose condition deteriorates in the first few days of life. This review aims to provide a concise summary on the presentation and management of various CCHDs and to emphasize on the role of timely diagnosis in the management.

2021 ◽  
Vol 22 (1) ◽  
Sarah Abu Arqub ◽  
Vaibhav Gandhi ◽  
Marissa G. Iverson ◽  
Maram Ahmed ◽  
Chia-Ling Kuo ◽  

Abstract Background The influence of different biological agents on the rate of orthodontic tooth movement (OTM) has been extensively reviewed in animal studies with conflicting results. These findings cannot be extrapolated from animals to humans. Therefore, we aimed to systematically investigate the most up-to-date available evidence of human studies regarding the effect of the administration of different biological substances on the rate of orthodontic tooth movement. Methods A total of 8 databases were searched until the 16th of June 2020 without restrictions. Controlled randomized and non-randomized human clinical studies assessing the effect of biological substances on the rate of OTM were included. ROBINS-I and the Cochrane Risk of Bias tools were used. Reporting of this review was based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results A total of 11 studies (6 randomized clinical trials and 5 prospective clinical trials) were identified for inclusion. Local injections of prostaglandin E1 and vitamin C exerted a positive influence on the rate of OTM; vitamin D showed variable effects. The use of platelet-rich plasma and its derivatives showed inconsistent results, while the local use of human relaxin hormone showed no significant effects on the rate of OTM. Limitations The limited and variable observation periods after the administration of the biological substances, the high and medium risk of bias assessment for some included studies, the variable concentrations of the assessed biological agents, the different experimental designs and teeth evaluated, and the variety of measurement tools have hampered the quantitative assessment of the results as originally planned. Conclusions and implications Despite the methodological limitations of the included studies, this systematic review provides an important overview of the effects of a variety of biological agents on the rate of tooth movement and elucidates the deficiencies in the clinical studies that have been conducted so far to evaluate the effectiveness of these agents in humans, providing some guidelines for future robust research. Trial registration PROSPERO (CRD42020168481,

Sign in / Sign up

Export Citation Format

Share Document